BMS's brivanib programme in doubt as second Phase III HCC trial fails
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb is "considering options" for the ongoing brivanib development programme after reporting that the Phase III BRISK-FL trial, investigating the drug versus sorafenib as a first-line treatment in patients with advanced hepatocellular carcinoma (HCC), had failed to meet its overall survival primary endpoint.